Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Summary

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.

News Radar provides aggregated summaries. Full content and copyright remain with the original publisher.